Clinical Trial Update: A Study of SGN-MesoC2 in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Seagen is conducting a Phase 1 study of SGN-MesoC2 in advanced solid tumors, including non-small cell lung cancer, ovarian cancer, pancreatic cancer, colorectal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Endometrial Cancer
• Malignant Mesothelioma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• SGN-MesoC2

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING